Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | AURKAIP1 | Q9NWT8 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034965 | 0.84 | SIGMAR1 (0.59) | SIGMAR1ALDH1A1KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL7200356 | 0.84 | KMT2A (0.55) | KMT2AALDH1A1KDM4EMEN1RXFP1 | |
| SCHEMBL20323781 | 0.83 | ALDH1A1 (0.51) | SIGMAR1KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL19264967 | 0.82 | SIGMAR1 (0.57) | SIGMAR1KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL11576737 | 0.82 | CA12 (0.59) | KMT2AALDH1A1KDM4EMEN1RXFP1 | |
| SCHEMBL2835133 | 0.81 | SMN1; SMN2 (0.68) | KMT2AALDH1A1KDM4EMEN1SMN1; SMN2 | |
| SCHEMBL5722103 | 0.81 | KMT2A (0.53) | KMT2AALDH1A1KDM4EMEN1RXFP1 | |
| SCHEMBL9343506 | 0.81 | SIGMAR1 (0.56) | SIGMAR1KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL20245336 | 0.81 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL10282720 | 0.81 | KMT2A (0.52) | SIGMAR1KMT2AALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102884047-B | 2-pyridone compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-11-25 | — | — | CN | disclosed |
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| CN-102884047-A | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO LTD | 2013-01-16 | — | — | CN | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2035372-A1 | MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008005338-A1 | MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | PDXK, HK1, KCNJ2 | SIGMAR1 4576/4885KMT2A 1631/4885ALDH1A1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.